A phase Ib/II study of fruquintinib in combination with paclitaxel as the second-line therapy for advanced gastric cancer.

ABSTRACT:

SUBMITTER: Zhang Y 

PROVIDER: S-EPMC9859731 | biostudies-literature | 2023 Jan

REPOSITORIES: biostudies-literature